Premium
A case of chronic myelomonocytic leukaemia and factor XI deficiency with a circulating anticoagulant
Author(s) -
Billon S.,
Blouch MT.,
EscoffreBarbe M.,
Le Niger C.,
Le Roux AM.,
Abgrall JF.
Publication year - 2001
Publication title -
haemophilia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.213
H-Index - 92
eISSN - 1365-2516
pISSN - 1351-8216
DOI - 10.1111/j.1365-2516.2001.00523.x
Subject(s) - factor xi , medicine , heterozygote advantage , parvovirus , clotting factor , immunology , gastroenterology , coagulation , allele , biochemistry , chemistry , virus , gene
Inhibitors against factor XI (FXI) have been frequently described in patients who acquired inhibitors (due to auto‐inmune disorders, malignancies or infections), but less often in those with a congenital deficiency of this factor, who had received plasma infusions. The present report concerns one such inhibitor found in the plasma of a patient with chronic myelomonocytic leukaemia and infected by B19 parvovirus, who was neither a heterozygote nor a homozygote for FXI deficiency, and who had no bleeding tendency despite a very low FXI level. Taking this case into account, we discuss and present the clinical and biological features of acquired FXI deficiency caused by an inhibitor.